{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:07:28Z","timestamp":1779322048551,"version":"3.51.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["75D30123P18258"],"award-info":[{"award-number":["75D30123P18258"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis C is a public health threat with national elimination targets, yet prevalence is challenging to measure. We utilized a novel approach to estimate hepatitis C prevalence among adults using residual sera from a large commercial laboratory.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional study in 50 states and the District of Columbia using a convenience sample of residual serum specimens (n = 81 483) among routine clinical specimens from adults aged 18\u2013\u226475\u2005years. We randomly sampled within 2 age groups (18\u2013\u226449\u2005years and 50\u2013\u226475\u2005years) during November 2023\u2013September 2024. Specimens were tested for hepatitis C virus (HCV) antibodies; reactive or equivocal results were reflexed to HCV ribonucleic acid (RNA) testing. We performed nested raking on the age\u2013sex distribution of the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among adults aged 18\u2013\u226475\u2005years, we estimated that the HCV antibody prevalence was 2.9% (95% CI, 2.8%\u20133.0%), corresponding to 6 887 000 (95% CI, 6 622 000\u20137 166 000) persons ever infected, and the HCV RNA prevalence was 0.7% (95% CI, .7%\u2013.8%), corresponding to 1 698 000 (95% CI, 1 554 000\u20131 845 000) persons currently infected. Viral clearance was lower among younger adults (63.8% [95% CI, 60.6%\u201366.9%]) than older adults (81.1% [95% CI, 78.9%\u201383.3%]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this analysis of residual sera from a commercial laboratory, we estimated that approximately 1.70 million adults were diagnosed with HCV infection during November 2023\u2013September 2024. Although underlying selection bias limits generalizability to the US population, the substantial burden estimated after a decade of available curative treatment underscores the need for concerted nationwide hepatitis C elimination efforts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag007","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:43:37Z","timestamp":1767789817000},"page":"e960-e966","source":"Crossref","is-referenced-by-count":0,"title":["Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023\u2013September 2024"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1687","authenticated-orcid":false,"given":"Megan G","family":"Hofmeister","sequence":"first","affiliation":[{"name":"Division of Viral Hepatitis, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"Symum","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5541-9535","authenticated-orcid":false,"given":"Brooke E","family":"Swanson","sequence":"additional","affiliation":[{"name":"Medical Affairs, Quest Diagnostics , Secaucus, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0215-5669","authenticated-orcid":false,"given":"Laurie K","family":"Barker","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2850-9047","authenticated-orcid":false,"given":"Harvey W","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-9641","authenticated-orcid":false,"given":"William W","family":"Thompson","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-995X","authenticated-orcid":false,"given":"William A","family":"Meyer","sequence":"additional","affiliation":[{"name":"Medical Affairs, Quest Diagnostics , Secaucus, New Jersey ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Viral Hepatitis, Centers for Disease Control and Prevention , Atlanta, Georgia ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"2026052019271848500_ciag007-B1","author":"Centers for Disease Control and Prevention"},{"key":"2026052019271848500_ciag007-B2","first-page":"1","article-title":"Estimated HIV incidence and prevalence in the United States, 2018\u20132022","volume":"29","author":"Centers for Disease Control and Prevention","year":"2024","journal-title":"HIV Surveillance Supplemental Report"},{"key":"2026052019271848500_ciag007-B3","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep4.1510","article-title":"Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States","volume":"4","author":"Paik","year":"2020","journal-title":"Hepatol Commun"},{"key":"2026052019271848500_ciag007-B4","author":"US Department of Health and Human Services"},{"key":"2026052019271848500_ciag007-B5","author":"Centers for Disease Control and Prevention"},{"key":"2026052019271848500_ciag007-B6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.7326\/M13-1133","article-title":"Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010","volume":"160","author":"Denniston","year":"2014","journal-title":"Ann Intern Med"},{"key":"2026052019271848500_ciag007-B7","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016","volume":"69","author":"Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"2026052019271848500_ciag007-B8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/ciad411","article-title":"Estimated prevalence and awareness of hepatitis C virus infection among US adults: National Health and Nutrition Examination Survey, January 2017-March 2020","volume":"77","author":"Lewis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026052019271848500_ciag007-B9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/hep.27978","article-title":"Toward a more accurate estimate of the prevalence of hepatitis C in the United States","volume":"62","author":"Edlin","year":"2015","journal-title":"Hepatology"},{"key":"2026052019271848500_ciag007-B10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/HEP.0000000000000927","article-title":"Estimating hepatitis C prevalence in the United States, 2017\u20132020","volume":"81","author":"Hall","year":"2025","journal-title":"Hepatology"},{"key":"2026052019271848500_ciag007-B11","author":"Quest Diagnostics Incorporated"},{"key":"2026052019271848500_ciag007-B12","author":"Siemens Medical Solutions USA, Inc"},{"key":"2026052019271848500_ciag007-B13","author":"Roche Diagnostics Limited"},{"key":"2026052019271848500_ciag007-B14","author":"US Department of Health and Human Services"},{"key":"2026052019271848500_ciag007-B15","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/978-1-4612-4380-9_41","volume-title":"Breakthroughs in statistics","author":"Efron","year":"1992"},{"key":"2026052019271848500_ciag007-B16","author":"Centers for Disease Control and Prevention"},{"key":"2026052019271848500_ciag007-B17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/cid\/ciac139","article-title":"Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014\u20132020","volume":"75","author":"Teshale","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026052019271848500_ciag007-B18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C","volume":"9","author":"Thomas","year":"2005","journal-title":"Clin Liver Dis"},{"key":"2026052019271848500_ciag007-B19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"2026052019271848500_ciag007-B20","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jhep.2016.04.030","article-title":"Factors associated with spontaneous clearance of chronic hepatitis C virus infection","volume":"65","author":"Bulteel","year":"2016","journal-title":"J Hepatol"},{"key":"2026052019271848500_ciag007-B21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cgh.2019.04.035","article-title":"Prevalence of spontaneous clearance of hepatitis C virus infection doubled from 1998 to 2017","volume":"18","author":"Seo","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026052019271848500_ciag007-B22","author":"Centers for Disease Control and Prevention"},{"key":"2026052019271848500_ciag007-B23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","article-title":"Vital signs: newly reported acute and chronic hepatitis C cases\u2014United States, 2009\u20132018","volume":"69","author":"Ryerson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026052019271848500_ciag007-B24","author":"US Census Bureau"},{"key":"2026052019271848500_ciag007-B25","first-page":"1071","article-title":"Hepatitis C care cascade incarcerated or detained persons and general population in California, 2011\u20132021","volume":"6","author":"Kaufman","year":"2023","journal-title":"Ann Gastroenterol Dig Syst"},{"key":"2026052019271848500_ciag007-B26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/003335491412900213","article-title":"Hepatitis C seroprevalence among prison inmates since 2001: still high but declining","volume":"129","author":"Varan","year":"2014","journal-title":"Public Health Rep"},{"key":"2026052019271848500_ciag007-B27","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1093\/infdis\/jiad227","article-title":"Estimates of hepatitis C seroprevalence and viremia in state prison populations in the United States","volume":"228","author":"Spaulding","year":"2023","journal-title":"J Infect Dis"},{"key":"2026052019271848500_ciag007-B28","author":"Siemens Healthineers"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag007\/66301286\/ciag007.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/5\/e960\/66301286\/ciag007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/5\/e960\/66301286\/ciag007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:27:25Z","timestamp":1779319645000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/5\/e960\/8416936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,8]]},"published-print":{"date-parts":[[2026,5,20]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag007","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,15]]},"published":{"date-parts":[[2026,1,8]]}}}